Literature DB >> 848658

Estimated median survival times of patients with colorectal cancer based on experience with 9,745 patients.

D T Silverman, J L Murray, C R Smart, C C Brown, M H Myers.   

Abstract

From the End Results Group file at the National Cancer Institute, 9,745 colorectal cancer patients diagnosed from 1965 through 1971 and classified as adenocarcinoma NOS were selected to evaluate the joint effect of various prognostic factors on MST. A technic was developed which enables a physician to estimate the MST for a patient with a given set of patient/disease characteristics. The results are also summarized in an appendix, allowing the physician to bypass the calculation and refer directly to the MST. These results will aid the physician in determining whether a patient is at sufficiently high risk to warrant adjuvant therapy. The survival experience of this broad historical group of patients with varying prognostic factors can also serve as a basis for comparison of results of studies on highly selected patients treated in various experimental ways.

Entities:  

Mesh:

Year:  1977        PMID: 848658     DOI: 10.1016/0002-9610(77)90531-1

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Laparoscopic versus open colorectal resections in patients with symptomatic stage IV colorectal cancer.

Authors:  Marco Ettore Allaix; Maurizio Degiuli; Giuseppe Giraudo; Alessandra Marano; Mario Morino
Journal:  Surg Endosc       Date:  2012-04-05       Impact factor: 4.584

2.  Elective palliative resection of incurable stage IV colorectal cancer: who really benefits from it?

Authors:  Renato Costi; Davide Di Mauro; Licia Veronesi; Andrea Ardizzoni; Pierfranco Salcuni; Luigi Roncoroni; Leopoldo Sarli; Vincenzo Violi
Journal:  Surg Today       Date:  2011-01-26       Impact factor: 2.549

3.  Extrahepatic biliary obstruction by metastatic colon carcinoma.

Authors:  A L Warshaw; J P Welch
Journal:  Ann Surg       Date:  1978-11       Impact factor: 12.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.